C-Peptide, Serum

Test ID: 

702865

CPT code:

84681

Synonyms:

C-Peptide

Connecting Peptide

Insulin C-Peptide

Proinsulin C-Peptide

Clinical Use:

The principal use of C-peptide is in the evaluation of hypoglycemia. Patients with insulin-secreting neoplasms have high levels of both C-peptide and endogenous insulin; in contrast, patients with factitious hypoglycemia will have low C-peptide levels in the presence of elevated (exogenous) serum insulin. C-peptide is also useful in evaluating residual beta-cell function in insulin-dependent diabetics, many of whom have antibodies that interfere with insulin assays. Glucagon-stimulated C-peptide concentration has been shown to be a good discriminator between insulin-requiring and non−insulin-requiring diabetic patients. The diagnosis of islet cell tumor is supported by elevation of C-peptide when plasma glucose is low.

Test Information:

This immunoassay is intended for the in vitro quantitative determination of C-peptide in human serum, plasma, and urine. The assay is intended for use as an aid in the diagnosis and treatment of patients with abnormal insulin secretion.
C-peptide is a single chain 31-amino acid (AA 33-63) connecting (C) polypeptide with a molecular weight of approximately 3021 daltons. In the process of biosynthesis of insulin, the C-peptide is formed as a byproduct together with insulin by the proteolytic cleavage of the precursor molecule proinsulin, stored in secretory granules in the Golgi complex of the pancreatic β-cells. Proinsulin, in turn, was cleaved from preproinsulin.
C-peptide fulfills an important function in the assembly of the two-chain insulin (α- and β-chain) structure and the formation of the two disulfide bonds within the proinsulin molecule. Insulin and C-peptide are secreted in equimolar amounts and released into circulation via the portal vein. As half of the insulin, but almost none of the C-peptide, is extracted in the liver, C-peptide has a longer half-life (about 35 minutes) than insulin; 5 to 10 times higher concentration of C-peptide persist in the peripheral circulation, and these levels fluctuate less than insulin.
The liver does not extract C-peptide, which is removed from the circulation by the kidneys and degraded, with a fraction excreted unchanged in the urine. The concentration in urine is about 20- to 50-fold higher than in serum. C-peptide concentrations are, therefore, elevated in renal disease.
In the past, C-peptide has been considered biologically inactive; however, recent studies have demonstrated that it is capable of eliciting molecular and physiological effects suggesting that C-peptide is in fact a bioactive peptide. There is evidence that C-peptide replacement, together with insulin administration, may prevent the development or retard the progression of long-term complications in type 1 diabetes.
Measurements of C-peptide, insulin, and glucose are used as an aid in the differential diagnosis of hypoglycemia (factitious hypoglycemia and hypoglycemia caused by hyperinsulinism) to ensure an appropriate management and therapy of the patients. To quantify the endogenous insulin secretion, C-peptide is measured basally, after fasting and after stimulation and suppression tests. Due to high prevalence of endogenous anti-insulin antibodies, C-peptide concentrations reflect the endogenous pancreatic insulin secretion more reliably in insulin-treated diabetics than the levels of insulin itself. Measurements of C-peptide may, therefore, be an aid in the assessment of a residual β-cell function in the early stages of type-1 diabetes mellitus and for the differential diagnosis of latent autoimmune diabetes of adults (LADA) and type-2 diabetes.
C-peptide measurements are also used to assess the success of islet transplantation and for monitoring after pancreatectomy.
Urine C-peptide is measured when a continuous assessment of β-cell function is desired or frequent blood sampling is not practical (eg, in children).3 C-peptide excretion in urine has been used to assess pancreatic function in gestational diabetes, and in patients with unstable glycemic control in insulin-dependent diabetes mellitus (IDDM).
Although testing for C-peptide is not requested for the routine monitoring of diabetes, it is a valuable tool for the individual therapeutic decisions which are essential for an optimal long-term metabolic control.
Elevated C-peptide levels may result from increased β-cell activity observed in hyperinsulinism, from renal insufficiency, and obesity. Correlation was also found between higher C-peptide levels and increasing hyperlipoproteinemia and hypertension. Decreased C-peptide levels are observed in starvation, factitious hypoglycemia, hypoinsulinism (NIDDM, IDDM), Addison disease, and after radical pancreatectomy.

Specimen Type:

Serum

Requested Volume: 

0.8 mL

Minimum Volume: 

0.3 mL

Container Type: 

Red-top tube or gel-barrier tube

Patient Preparation: 

Patient should fast for 14 to 16 hours for basal values.

Collection:

If a red-top tube is used, transfer separated serum to a plastic transport tube. Avoid hemolysis.

Storage Instructions:

Refrigerate.

Stability Requirements:

Temperature

Period

Room temperature

1 day

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Rejection Criteria

Citrate plasma specimen

Return Back to Test Directory

MCI Diagnostic

Providing top patient care with fast results. 

7018 South Utica Avenue

Tulsa, Oklahoma 74136

Hours of Operation

Mon - Sat: 7 AM-11 PM

Sun: 7 AM-3 PM

COVID-19 Drive-Thru Hours

Mon-Fri: 9 AM-6 PM

Sat: 9 AM-3 PM

More Information - Click Here

Government Contract

DUNS # 125722608

Cage Code: 3FPQ3

COVID-19

COVID-19 Fee & Pricing